Anagha Bangalore Kumar, M.B.B.S.

  1. Dermatologist
  1. Bangalore Kumar A, Asamoah E, Baum CL. Retrospective Pilot Study: Squamous Cell Carcinoma in Situ of the Head and Neck Treated With Topical 5-Fluorouracil. Dermatol Surg. 2025 Apr 10; 51 (9):898-900
    View PubMed
  2. Bangalore Kumar A, Trischman T, Asamoah E, Todd A, Vidal NY, Demer AM. Mohs Micrographic Surgery With Melanocytic Immunostains for T1a/b Invasive Melanoma Yields <1% Local Recurrence and Disease-specific Mortality. Dermatol Surg. 2025 Feb 1; 51 (2):123-126 Epub 2024 Sept 30
    View PubMed
  3. Asamoah EM, Demer AM, Trischman TE, Bangalore Kumar A, Vidal NY, Wagner LH. Immunohistochemistry-Assisted Mohs Surgery for Invasive Eyelid and Periorbital Cutaneous Melanoma. Dermatol Surg. 2025 Feb 01; 51(2):127-133. Epub 2024 Oct 23.
    View PubMed
  4. Rames MM, Campbell E, Asamoah E, Trischman T, Kumar AB, Vidal NY, Demer A. Mohs Micrographic Surgery for Invasive Melanoma Allows for Tissue Preservation Compared With Wide Local Excision: A Retrospective Cohort Study. Dermatol Surg. 2024 Nov 1; 50 (11):997-999 Epub 2024 June 18
    View PubMed
  5. Trischman T, Bangalore Kumar A, Asamoah EM, Todd A, Vidal NY, Demer AM. Risk factors associated with tumor upstaging in melanomas treated with Mohs micrographic surgery with melanocytic immunohistochemistry. JAAD Int. 2024 Sep; 16:3-8. Epub 2024 Mar 26.
    View PubMed
  6. Campbell E, Trischman T, Kumar AB, Asamoah E, Vidal N, Demer A. Patients with head and neck invasive melanoma have nearly 1:4 risk of separate lifetime primary melanoma. Arch Dermatol Res 2024 Aug 24; 316 (8):568
    View PubMed
  7. Campbell E, Trischman T, Kumar AB, Asamoah E, Vidal N, Demer A. Patients with head and neck invasive melanoma have nearly 1:4 risk of separate lifetime primary melanoma. Arch Dermatol Res. 2024 Aug 24; 316(8):568.
    View PubMed
  8. Kumar AB, Asamoah EM, Wetter DA, Davis MDP, Alavi A. Clinical Characteristics and Inciting Agents for Pseudoporphyria: The Mayo Clinic Experience, 1996-2020. Adv Skin Wound Care. 2024 Aug 01; 37(8):406-411.
    View PubMed
  9. Bangalore-Kumar A, Jin MF, Kunkel H, Sathe N, Hall MR, Drage LA, Youssef M, Yang YW, Yiannias JA, Killian J, Davis MDP. Results of Patch Testing to Botanicals: Review of the Mayo Clinic Experience Over 2 Decades (1997-2017). Dermatitis. 2024 Jan-Feb; 35(1):43-48. Epub 2023 Nov 24.
    View PubMed
  10. Reinhart JP, Kumar AB, Casanegra AI, Rooke TW, Sartori-Valinotti JC, Tollefson MM, Klaas KM, Davis DM. Bridging the gap in BASCULE syndrome: A retrospective case series of a recently described clinical entity. Pediatr Dermatol. 2024 Jan-Feb; 41(1):46-50. Epub 2023 Nov 28.
    View PubMed
  11. Bangalore Kumar A, Peters MS, Jakub JW, Harmsen W, Baum CL. Primary cutaneous melanoma features predict development of in-transit metastases/satellite lesions: Mayo Clinic experience, 2010 to 2014. J Am Acad Dermatol. 2023 Feb; 88(2):455-457. Epub 2022 Jun 13.
    View PubMed
  12. Bangalore Kumar A, Lehman JS, Johnson EF, Cantwell HM, Sartori Valinotti JC, Sokumbi O, Davis MDP, Wetter DA. Reactive granulomatous dermatitis as a clinically relevant and unifying term: a retrospective review of clinical features, associated systemic diseases, histopathology and treatment for a series of 65 patients at Mayo Clinic. J Eur Acad Dermatol Venereol. 2022 Dec; 36(12):2443-2450. Epub 2022 May 26.
    View PubMed
  13. Lalla SC, Kumar AB, Lehman JS, Lohse CM, Brewer JD. Association of BRAF V600E Status of Incident Melanoma and Risk for a Second Primary Malignancy: A Population-Based Study. Cutis. 2022 Sep; 110(3):150-154.
    View PubMed
  14. Bangalore Kumar A, Bryce AH, Vishnu P, Markovic SN, McEvoy MT. Associations of cutaneous immune-related adverse effects of immunotherapy with treatment response in patients with metastatic melanoma. SKIN: Journal of Cutaneous Medicine. 2021; 5 (2):108-17
  15. Vera Aguilera J, Paludo J, McWilliams RR, Zhang H, Li Y, Kumar AB, Failing J, Kottschade LA, Block MS, Markovic SN, Dong H, Dronca RS, Yan Y. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res. 2020 Aug; 30(4):364-375.
    View PubMed
  16. França K, Kumar A, Castillo D, Jafferany M, Hyczy da Costa Neto M, Damevska K, Wollina U, Lotti T. Trichotillomania (hair pulling disorder): Clinical characteristics, psychosocial aspects, treatment approaches, and ethical considerations. Dermatol Ther. 2019 Jul; 32(4):e12622. Epub 2018 Aug 28.
    View PubMed
  17. Kumar AB, Blixt EK, Drage LA, El-Azhary RA, Wetter DA. Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013. J Am Acad Dermatol. 2019 Jun; 80(6):1658-1663. Epub 2019 Jan 29.
    View PubMed
  18. Bangalore Kumar A, Maus R, Markovic SN. Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New. Mayo Clin Proc. 2018 Jul; 93(7):917-936. Epub 2018 Jun 07.
    View PubMed
  19. Yan Y, Kumar AB, Finnes H, Markovic SN, Park S, Dronca RS, Dong H. Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Front Immunol. 2018; 9:1739. Epub 2018 Jul 27.
    View PubMed
  20. Kumar AB, Shamim H, Nagaraju U. Premature Graying of Hair: Review with Updates. Int J Trichology. 2018 Sep-Oct; 10(5):198-203.
    View PubMed
  21. França K, Kumar A, Fioranelli M, Lotti T, Tirant M, Roccia MG. The history of Botulinum toxin: from poison to beauty. Wien Med Wochenschr. 2017 Oct; 167(Suppl 1):46-48. Epub 2017 Mar 15.
    View PubMed
  22. Kumar A. Hypohidrotic ectodermal dysplasia - a rare case report in siblings Int J Sci Res. 09/09/2015; 4.